



# Corporate Presentation

August 2019

SFE  
LISTED  
NYSE



- Founded in 1953 and NYSE-listed since 1971
- Safeguard provides capital and experience to growing healthcare, digital media and technology businesses
- Provides financial and management support for existing partner companies
- Distinguished track record of fostering innovative disruptive market leaders
- Attractive portfolio of tech-enabled companies across several verticals
- Safeguard adopted a change in business strategy and operations in early 2018
- Have realized over \$180 million in cash proceeds since change in strategy
- Using partner company monetization events to return value to shareholders

# Safeguard Scientifics, Inc. Value



- SFE Market Capitalization: At \$12 per share, ~\$250 million
- SFE: Positive Net Cash Position
- Carrying Value of Ownership Interests at June 30, 2019: \$77 million
- Active Capital in Portfolio (15 companies): \$202 million
- Exit Value of Portfolio: TBD

# Partner Companies: Key Facts



	Holdings at 12/31/18	Holdings at 6/30/19
<b>Total Capital Deployed</b>	\$263.8 million	\$202.2 million
<b>Total Number of Partner Companies</b>	21	15
<b>Average Age with Safeguard</b> (number of years since initial Safeguard capital deployment)	~5 years	~5 years

# Typical Partner Companies



## Target Company Profile

**Technology-driven businesses** in healthcare, financial services or digital media.

Particular focus on enabling technologies involving:

 **Enhanced Security**

 **Artificial Intelligence\***

\* Includes Predictive Analytics and Machine Learning

## Deal Size

Initial Capital:  
**\$5M - \$15M**

Follow-On Capital:  
**\$5M - \$10M**

Total Target Size:

**Generally Less Than \$25M**

## Deal Structure

Position:

**Typically Lead Financial Sponsor**

Ownership:  
**20% - 50%**

Involvement:  
**Board Representation**

# Portfolio of Companies: Overview



## Technology



Healthcare




Financial Services and Other



Digital Media

# Partner Companies: By Revenue Stage


(at 6/30/2019)



# Aggregate Partner Company Revenue



**2019 Aggregate Partner Company Revenue Projected to Increase 10% – 18% YoY**



Aggregate revenue guidance for 2018 and prior years reflects revenue on a net basis for the remaining partner companies. Safeguard reports the revenue of its equity and cost method partner companies on a one-quarter lag basis. Revenue for all years has been revised to exclude companies that were exited or impaired.

# Aktana—Company Overview



## Company Overview

Market Segment:	Sales Decision Support / Marketing Automations (Life Sciences / Medtech)
Headquarters:	San Francisco, CA
CEO:	David Ehrlich
<ul style="list-style-type: none"><li>- Aktana is an AI-enabled life sciences marketing decision support solution that helps sales and marketing teams to optimize go-to-market strategies at the brand level</li><li>- Helps customers improve their commercial effectiveness by delivering data-driven insights and suggestions directly to sales reps, coordinating multi-channel actions, and providing insight regarding which strategies work best for customers</li><li>- Aktana's Decision Support System ("DSE") provides next-best-action insights for sales reps, while the Learning Platform allows the engine to learn which suggestions are optimal</li></ul>	

## Thesis

- Total addressable market is approximately \$2B for pharma and biotech sales rep decision support
- Focus on the life sciences market has contributed to multi-year growth rates of more than 100% in relationships with over half of the world's top 15 pharmaceutical companies
- Real-world validation and proven ROI across therapeutic categories and geographies
- Robust partner ecosystem
- Serves brands across a range of therapeutic areas in multiple geographies

## Summary

Origin:	June 2016
Capital:	\$10.2M
Ownership:	19% Primary
Financing Rounds:	Series B, Series C
Other Investors:	Leerink Transformation Partners, Novartis (dRx), HLM Venture Partners, Starfish Ventures
Board Member:	Gary Kurtzman

## Revenue Model

Aktana prices its platform separately for the decision support engine (DSE) (aka top layer)—which provides smart suggestions and insights to pharmaceutical sales representatives within their workflow to help them make better every day decisions—and the Learning Platform (bottom layer). For DSE, Aktana licenses the software based on a per rep per brand basis according to size and number of reps. For the Learning Platform, Aktana charges an annual fee.

## Competitors

Veeva, Salesforce, IMS, ZS Associates, Vymo, Customer Insourcing

# Clutch—Company Overview



## Company Overview

Market Segment:	Customer Rewards and Loyalty
Headquarters:	Ambler, PA
CEO:	Ned Moore
<ul style="list-style-type: none"> <li>- A leading wholistic solution to a fragmented industry, Clutch offers customer relationship management and a mobile commerce platform that unifies gifting, loyalty and shopping to bring the most relevant information to consumers and the most targeted customers to merchants</li> <li>- The Company offers a marketing platform that serves as a customer hub delivering deep intelligence, derived from real-time behaviors and transactions across in-store, online, mobile and social channels</li> <li>- Revenue is comprised of four components: contracted recurring, transactional, services and marketing. The majority of revenue is derived from transaction-based services. Clutch also earns a small portion via on-boarding fees and is looking at the data monetization potential</li> </ul>	

## Thesis

- The consumer and loyalty management market is focused on delivering to premier brands the ability to maximize relationships with their customers along with lifetime value, and is estimated to reach a value of \$6.8Bn by 2023, representing a 5-year CAGR of 21.1% from 2018
- Broad potential client base includes any consumer business that uses gift and loyalty programs
- Well positioned to unify the very fragmented, non-standardized set of rewards and loyalty solutions utilized today across major brands, and to execute on strategic and referral partnerships to drive growth
- Expanding into new verticals, such as banking and financial services, food, hospitality and healthcare, which help balance cyclicalities in the core verticals and have higher average order value

## Summary

Origin:	February 2013
Capital:	\$16.6M
Ownership:	41% Primary
Financing Rounds:	Series A, Series B, Series C in process
Other Investors:	NewSpring Capital, Ben Franklin Technology Partners, Empactful
Board Member:	Steve Grenfell

## Revenue Model

The majority of Clutch’s revenue is transaction-based, while a small portion is via on-boarding fees. The potential client base includes any consumer business that uses gift and loyalty programs. Once Clutch signs a client, the client pays Clutch a transaction fee for users that use the loyalty and gifting features platform. The client is incentivized to onboard as many users onto the gifting and loyalty platform as it can, because this will ultimately lead to more transactions and purchases for the client. Clutch believes there are also data monetization opportunities once the platform is integrated.

## Competitors

eGain Corporation, Five9, Inc., Hansen Technologies, Ltd., MIND C.T.I, Ltd., Salesforce.com, Inc., Zendesk, Inc., NetSuite Inc., Bazaarvoice, Inc.



## Company Overview

Market Segment:	Digital Ad Management and Analytics
Headquarters:	New York, NY
CEO:	John Nardone
<ul style="list-style-type: none"> <li>- A data-driven ad management and analytics technology company that uses data to personalize advertising in real-time, analyze its effectiveness and enable optimization that drives better engagement and ROI for sophisticated global brands</li> <li>- Offers both front-end tools like campaign setup, asset creation, HTML builders &amp; decision trees as well as back end capabilities that, together, allow analytics and reporting to be as strong as the front-end functions</li> <li>- Generates revenue via contracts with clients for creative delivery, media measurement and advertising effectiveness solutions</li> <li>- Provides online marketing services pursuant to the agreements with corporate customers and marketing partners</li> </ul>	

## Thesis

- Safeguard originally invested in Spongecell a programmatic, dynamic creative advertising tool which was merged into Flashtalking in 2018
- U.S. internet advertising market spend hit more than \$80B in 2017 and is expected to hit approximately \$115B by 2021. Globally, spend reached more than \$225B in 2017 and is anticipated to grow at a 9% CAGR through 2021 (eMarketer)
- Flashtalking is well positioned to continue addressing not only the ad-serving and targeting segments of the market, but also the Dynamic Creative Optimization (“DCO”) market within the high-growth mobile, video, rich media and display sub-sectors
- Blue chip client base focused across Retail / E-commerce, Travel, and Telco

## Summary

Origin:	January 2012 (via sale of Spongecell)
Capital:	\$19.1M
Ownership:	10% Primary
Financing Rounds:	Private Equity-backed
Other Investors:	TA Associates
Board Member:	Steve Grenfell (Observer)

## Revenue Model

Flashtalking enters into contracts with clients for creative delivery, media measurement and advertising effectiveness solutions. Through their DCO segment (augmented with Spongecell), they provide online marketing services pursuant to the agreements with corporate customers and marketing partners. Cost per Thousand Impressions, Cost per Click and Cost per Action represent the three most common ways in which online advertising is sold and purchased.

## Competitors

Criteo, Google, Inc., IACI, Marin Software Incorporated, Sizmek, Inc., Kenshoo

# InfoBionic—Company Overview



## Company Overview

Market Segment: Patient Monitoring (Cardiac)

Headquarters: Lowell, MA

CEO: Stuart Long

- A digital health company focused on creating superior patient monitoring solutions for chronic disease management with an initial market focus on cardiac arrhythmias
- Has 510(k) clearance from the U.S. Food and Drug Administration (“FDA”) for MoMe® Kardia, a wireless, remote monitoring system designed to aid physicians in their diagnosis of cardiac arrhythmia
- The proprietary software analyzes the data and flags incidents for physician review on a Web-based physician portal
- BIOTRONIK is the exclusive distributor of MoMe® Kardia in the U.S.

## Thesis

- The global addressable market for monitoring cardiac arrhythmia and related events is estimated to be approximately \$3B worldwide, including \$1B in the U.S.
- Innovative SaaS revenue model, which includes an upfront device sale followed by a monthly subscription fee for unlimited use of the company’s cloud-based diagnostic service and portal
- MoMe® Kardia displaces IDTFs and redirects reimbursement economics to the ordering physicians, encouraging adoption

## Summary

Origin: March 2014

Capital: \$22.0M

Ownership: 25% Primary

Financing Rounds: Series B, Series C

Other Investors: Eagle Investments, BCBS KS, Broadview Ventures, Excel Venture Management, HealthTechCapital, Zaffre Investments

Board Member: Brian Sisko

## Revenue Model

One of InfoBionic’s most differentiated features is its SaaS revenue model, which includes an upfront device sale followed by a monthly subscription fee for unlimited use of the company’s cloud-based diagnostic service and portal.

## Competitors

iRythm, BioTelemerty, AliveCor, Medi-Lynx, Zywie, Medtronic, Abbott, GE Healthcare, Philips, OSI Systems

# Lumesis—Company Overview



## Company Overview

Market Segment:	Financial Analytics / Compliance
Headquarters:	Stamford, CT
CEO:	Gregg Bienstock
<ul style="list-style-type: none"> <li>- Lumesis is a financial technology company focused on providing business efficiency and compliance solutions via its DIVER platform to hundreds of clients and over 45,000 users in the municipal bond marketplace</li> <li>- The DIVER platform from Lumesis delivers technology and data solutions helping firms efficiently meet credit, regulatory and risk needs</li> <li>- The Company's solutions enable portfolio managers, investment advisors, compliance professionals, financial advisor networks and issuers / underwriters to heat-map portfolios against local economic scenarios, benchmark against industry indices, manage their portfolios against internal credit and risk models, and monitor issuer disclosures</li> </ul>	

## Thesis

- The municipal bond market has doubled in size over the past 10 years, with over \$3.7 trillion of U.S. municipal debt outstanding among 45,000 unique issuers
- The Company is solely dedicated to the municipal bond market, which has been historically underserved by technology providers
- Lumesis works with over 200 institutional clients, including blue-chip broker dealers, asset managers, insurance companies, mutual funds and rating agencies
- Only company that serves the entire municipal bond market, including buy-side, sell-side and legal / compliance
- Large IP portfolio and proprietary database create significant barriers to entry

## Summary

Origin:	February 2012
Capital:	\$6.3M
Ownership:	44% Primary
Financing Rounds:	Series A, Series B
Other Investors:	NextStage Capital, Jim Ashton (JA3 Partners)
Board Member:	Brian Sisko, Steve Grenfell

## Revenue Model

Lumesis licenses financial software products to the municipal fixed income market to be used as analytical and compliance tools. Customers buy licenses on an enterprise / per seat per issuance basis, usually covering an annual period. Lumesis also sells data to financial market participants.

## Competitors

ValueLine, Inc., Fidessa Group plc, Reis, Inc., Investnet, Inc., Forrester Research Inc., Financial Engines, Inc., DAC, Investment Technology Group, Inc.

# MediaMath—Company Overview



## Company Overview

Market Segment:	Digital Advertising / Marketing
Headquarters:	New York, NY
CEO:	Joe Zawadzki
<ul style="list-style-type: none"> <li>- Global ad technology company that enables advertisers to optimize their digital advertising spend across ad exchanges via an algorithmic trading platform</li> <li>- The Company's media buying platform, TerminalOne, allows MediaMath to be a conduit for every transaction and provides the Company with the ability to analyze every transaction, identify inefficiencies within the market and ultimately provide an automated optimization engine to maximize performance for ad agencies and brands</li> <li>- Offered as both a Managed Service and a Self-Service SaaS Platform</li> </ul>	

## Thesis

- According to eMarketer, worldwide digital ad spending is expected to reach \$328B in 2019 and represents 39% of total paid media outlay; spend is expected to see double-digit growth through at least 2020
- MediaMath is well positioned to capitalize on ad spending growth given revenue is generated based on customer spend through the platform
- The Company's media buying platform, TerminalOne, effectively integrates all of the exchanges under one platform, thereby filling a deep demand for intelligent buying
- Diversified, blue-chip customer base of 4,000+ advertisers globally, including two-thirds of the Fortune 500

1. List is not exhaustive

## Summary

Origin:	July 2009
Capital:	\$15.5M*
Realizations to Date:	\$45.0M*
Ownership:	14% Primary
Financing Rounds:	Series B, Series C
Other Investors:	Akamai Technologies, Catalyst Partners, QED Investors, Observatory Capital Management, Spring Lake Equity Partners, Vocap Ventures
Board Member:	Brian Sisko (Observer)

\*Reflects sale-back of equity related to \$10M in invested capital in 2018 to MediaMath for \$45M

## Revenue Model

MediaMath's TerminalOne Marketing Operating System enables clients to acquire and optimize digital advertising. MediaMath earns revenue as a percentage of customer spend through the platform. In addition, MediaMath generates revenues from services provided based on achievement of targeted deliverables as specified in the agreements with their customers. Deliverables are typically based on delivery of impressions, clicks to a specified web site or specified user actions.

## Competitors

Adobe Systems, Google, Criteo, Trade Desk, Rubicon Project, Telaria



## Company Overview

Market Segment:	Human Capital Management
Headquarters:	Boston, MA
CEO:	Jan Bruce

- SaaS-based proprietary resilience development solutions powered by predictive analytics and AI for organizations to manage their human capital and develop engaged, agile workforces
- The Company offers solutions for individual employees (Engage), managers and teams (Empower), and HR and Benefits managers (Gateway and Collaborate). Solutions are multi-modal and global
- The solution increases engagement, productivity, and performance and improved outcomes in retaining and developing top talent and managing stress, health, and well-being
- Its product suite is sold as a per-employee-per-year SaaS delivered in a desktop or mobile environment

## Thesis

- Human Capital Management (“HCM”) software market was estimated at \$14.5B in 2017, and is expected to grow to \$22.5B by 2023<sup>1</sup>
- Current customer base of over 40 Fortune 500 clients and in 60+ countries
- Contracts are 2-3 years with each year typically paid upfront by customers
- Demonstrable ROI within key early adopters, including Comcast, HP, and JPMorgan
- Emphasis on HCM (versus wellness) opens up new potential customers and strategic channel partners, maximizing topline growth potential
- Opportunity to maximize products being sold to a single customer (land and expand)

1. Based on industry and market reports

## Summary

Origin:	April 2015
Capital:	\$13.0M
Ownership:	33% Primary
Financing Rounds:	Series B, Series C, Series C extension
Other Investors:	HLM Venture Partners, Chrysalis Ventures
Board Member:	Gary Kurtzman

## Revenue Model

meQuilibrium’s product is sold as a PEPY software-as-a-service delivered in a desktop or mobile environment. Most current contracts are 2-3 years in length and each year is typically paid upfront by customers.

## Competitors

Castlight Health (CSLT), Limeade, Happify, Headspace, Optum, Success Factors (SAP), Whil, others

# Moxe—Company Overview



## Company Overview

Market Segment:	Interoperability
Headquarters:	Madison, WI
CEO:	Dan Wilson
<ul style="list-style-type: none"> <li>- Provides a clinical data clearinghouse, creating a two-sided network facilitating the bi-directional exchange of clinical, analytic, and administrative data between health systems and payers</li> <li>- Its key product, Substrate, serves as an electronic medical record integration platform, facilitating the real-time exchange data between payers and their provider networks for risk adjustment and other use cases</li> <li>- Moxe's second product, Convergence, creates a customer portal directly in the provider's EMR workflow, allowing payers to share data and actionable insights directly with physicians</li> <li>- Currently developing additional products aimed at improving clinical data workflows for payer and health system customers</li> </ul>	

## Thesis

- Moxe plays in large and growing spaces; interoperability market is \$1.9B (7.4% CAGR); healthcare analytics market is \$8.9B (27% CAGR); value-based care / population health management software market is expected to reach \$32B by 2020
- Current market for chart retrieval estimated >\$300M; HCC reconciliation and risk adjustment larger (\$5B+) with significant incumbents; current processes slow and manual
- Moxe offers better, faster, cheaper solution with more complete data; multiple uses cases for payers, providers, pharma, and patients
- Opportunity to leverage network effects to accelerate scaling

## Summary

Origin:	September 2016
Capital:	\$5.5M
Ownership:	32% Primary
Financing Rounds:	Series A / Bridge
Other Investors:	UPMC Enterprises
Board Member:	Gary Kurtzman

## Revenue Model

Moxe has priced its solution on a per health system site basis (\$22.5K per year per site) and a transactional basis (\$7 per patient chart pulled). Moving forward, Moxe is implementing PMPM pricing for payer customers by health system site to improve revenue predictability.

## Competitors

Availity, Ciox, Experian, Innovaccer, Inovalon, McKesson Corporation, MRO Corp, Navinet (NantHealth), other interoperability solutions



## Company Overview

Market Segment: Healthcare Analytics / AI

Headquarters: New York, NY

CEO: Sundeep Bhan

- Prognos aggregates, harmonizes and analyzes clinical diagnostic data for life sciences, diagnostic companies, and payers, aiming to improve health by tracking and predicting disease
- The Prognos Registry of 22 billion clinical records for 200 million patients in over 50 disease areas enables earlier identification of patients who can benefit from enhanced treatment decision making and risk management
- The Company operates in two verticals – Life Sciences and Payers. In the Life Sciences segment, Prognos contracts with biopharma firms to identify patients who are candidates for drug treatment.
- In the Payer segment, Prognos contracts with plans for various population risk use cases annually and has revenue share agreements with labs to secure access to the data

## Thesis

- Large, unique clinical data asset; proprietary technology and data science/machine learning/AI capabilities; data network effects
- Multiple use cases applicable to pharma, payers, labs, and PBMs with potential for expansion into provider space
- Based on current monetization strategies, the total addressable healthcare analytics market for Prognos' products is estimated to reach \$5.5bn+
- Strategic partnership opportunities

## Summary

Origin: November 2011

Capital: \$12.6M

Ownership: 29% Primary

Financing Rounds: Series A, Series B, Series C

Other Investors: Hikma Ventures, Cigna Ventures, ARC Angel Fund, Merck GHIF, GIS Strategic Ventures (Guardian Life) , Hermed Capital, Maywic Strategic Inv

Board Member: Gary Kurtzman (Chair)

## Revenue Model

Prognos operates in two verticals – Life Sciences and Payers. In the Life Sciences segment, Prognos contracts with biopharma firms for potential patient identification solutions. In the Payer segment, Prognos contracts with plans for various population risk use cases annually and has revenue share agreements with labs to secure access to the data.

## Competitors

IQVIA, Health Verity, LabCorp, Quest, Symphony Health



## Company Overview

Market Segment:	Digital Ad Management / Paid Search
Headquarters:	San Mateo, CA
CEO:	Chaitanya Chandrasekar
<ul style="list-style-type: none"> <li>- QuanticMind provides a SaaS-based, next generation Search Engine Marketing (“SEM”) platform for Paid Search that develops ad management point solutions using data science and machine learning algorithms to yield better search results for clients</li> <li>- Its solution enables the clients to enhance their visibility to client customers generating these search queries</li> <li>- In addition, insights the platform generates help a client determine the efficiency and effectiveness of their marketing campaigns and measure customer interaction with their listings in online search</li> <li>- Pricing is determined by a tiered schedule based on the gross amount of spend managed by the platform, averaging ~2% of spend</li> </ul>	

## Thesis

- QuanticMind competes in the digital advertising management sector, a large, established market with a well-defined competitor set; the market opportunity is estimated at more than \$15B annually
- Typically signs annual contracts with customers, providing QuanticMind with revenue visibility
- More nimble bidding option than traditional resources
- Less likely to be replaced given minimal % of total ad spend for customers

## Summary

Origin:	June 2015
Capital:	\$13.2M
Ownership:	25% Primary
Financing Rounds:	Series B
Other Investors:	Foundation Capital, Cervin Ventures
Board Member:	Brian Sisko

## Revenue Model

QuanticMind sells its solution as a software-as-a-service directly to advertisers as well as through agencies. Contracts are typically one-year in length and billed monthly. Pricing is determined by a tiered schedule based on the gross amount of spend managed by the platform.

## Competitors

Google, Marin, Adobe, Kenshoo, in-house DIY solutions

# Sonobi—Company Overview



## Company Overview

Market Segment:	Premium Programmatic Ad Technology
Headquarters:	Winter Park, FL
CEO:	Michael Connolly
<ul style="list-style-type: none"> <li>- Proprietary Jetstream platform enables publishers to make premium advertising inventory available on their websites and mobile platforms to brands, agencies and demand side platforms “DSPs”, (e.g., MediaMath, The Trade Desk and AppNexus) in a data rich and highly targeted environment</li> <li>- Efficient and scalable marketplace enabling premium (comScore250) publishers to work with brands to provide differentiated access to their consumers</li> <li>- Sonobi becomes an alternative to Google, Facebook, and, increasingly Amazon, for publishers</li> </ul>	

## Thesis

- The premium online advertising market is anticipated to grow to \$43B (eMarketer)
- Sonobi is well-positioned to develop this important advertising segment, with strong technology, synergistic partnerships, a high-quality publisher base and a growing pipeline
- Sonobi sells directly to large, premium publishers and then partners with large advertisers and other demand side players such as MediaMath and AppNexus
- Industry has standardized a percent of spend as an accepted pricing model

## Summary

Origin:	May 2015
Capital:	\$13.4M (including \$8M cumulative bridge)
Ownership:	22% Primary
Financing Rounds:	Series A
Other Investors:	Merkle
Board Member:	Gary Kurtzman

## Revenue Model

Sonobi sells directly to large, premium publishers and then partners with large advertisers and other demand side players such as MediaMath and AppNexus. Revenue is volume-driven. The industry has standardized a percent of spend as an accepted pricing model.

## Competitors

Criteo, The Rubicon Project, Inc., Sizmek, Inc., Casale Media / Index Exchange

# Syapse—Company Overview

syapse



## Company Overview

Market Segment:	Precision Medicine
Headquarters:	San Francisco, CA
CEO:	Ken Tarkoff
<ul style="list-style-type: none"> <li>- Multi-sided platform creating a data network effect in order to improve the way cancer and other diseases are treated                     <ul style="list-style-type: none"> <li>• Health systems contribute clinical and other data to the platform and receives clinical and business insights</li> <li>• Pharma, on the other side of the platform, purchases insights and delivers information back to health systems</li> </ul> </li> <li>- Syapse collects and networks data from siloed hospital and laboratory enterprise systems (Syapse Network) allows the Company to provide solutions for pharma including real world evidence generation, identification of patients for clinical trials and hub services</li> <li>- Ecosystem partnerships with Roche, Amgen, others TBA</li> </ul>	

## Thesis

- Syapse is initially focused on oncology, opportunity to leverage the platform other disease verticals anticipated in 2020 and beyond
- Scalability allows targeting of large community health systems (50% of oncology pts in U.S) and ex-U.S, expansion
- \$9B U.S./\$15B Global market opp. from pharma partnerships and \$250M U.S./\$1B Global market opp. from health systems in oncology
- Multi-year agreement opportunities with health systems
- Pharma partnership base payments plus milestones

## Summary

Origin:	June 2014
Capital:	\$18.6M
Ownership:	20% Primary
Financing Rounds:	Series B, Series C, Series D, Series E
Other Investors:	Amgen Ventures, Ascension Ventures, Intermountain Healthcare Innovation Fund, Merck GHIF, Medidata Ventures, Roche, GE Ventures, Social Capital
Board Member:	Gary Kurtzman (Chair)

## Revenue Model

Syapse currently signs multi-year license agreements with health systems. Additionally, Syapse is monetizing pharma and other ecosystem relationships.

## Competitors

Flatiron Health, Cota, Tempus Health, Concerto



## Company Overview

Market Segment:	Medical Device
Headquarters:	Malvern, PA
CEO:	Mark Foster
<ul style="list-style-type: none"> <li>- Integrated camera-enabled technology that provides a clinical solution optimized for the physicians' office to improve orthopedic diagnostics</li> <li>- Trice Medical's FDA-approved 510(k)-cleared device, mi-eye 2, is a disposable, handheld 2.2mm arthroscope, consisting of a needle with an integrated camera and a light source designed for in-office.</li> <li>- The products help physicians with real-time analysis, faster treatment, and schedule patients for surgery immediately</li> <li>- Recent addition of companion in-office ultrasound device, mi-Ultra, for endoscopic orthopedic procedures</li> <li>- IP for other indications including neurosurgery, ob-gyn, respiratory, ENT and veterinary</li> </ul>	

## Thesis

- mi-Eye addressable market (U.S.) is more than 8 million orthopedic-focused MRI exams are conducted each year.
- Positive economics for payers and providers
  - Private insurers (cover approximately 80% of all sports medicine injuries) pay an average of \$1.5-2K per MRI— implying an addressable market opportunity for Trice of ~\$15B
  - Average selling price provides positive economics to providers while delivering more immediate and definitive care
- Strong proprietary position provides the ability to enter additional verticals and partner/license.

## Summary

Origin:	July 2014
Capital:	\$10.2M
Ownership:	17% Primary
Financing Rounds:	Series B, Series C
Other Investors:	Charter Capital, BioStar Ventures, HealthQuest Capital, Michigan Employees Retirement System, Smith & Nephew
Board Member:	Gary Kurtzman (Chair)

## Revenue Model

Trice sells the mi-eye needles for approximately \$400 per unit, which is consistent with the disposable price point of the VisionScope technology. The companion tablet is offered for a list price of \$1,500.

## Competitors

Arthrex, Karl Storz, Smith & Nephew, Stryker, Depuy Synthes, CONMED, Biomet-Zimmer, J&J

# WebLinc—Company Overview



## Company Overview

Market Segment: Online Retail and eCommerce

Headquarters: Philadelphia, PA

CEO: Darren Hill

- WebLinc has 2 product offerings:
  - Workarea - a modern, digital commerce technology platform for growing e-Commerce focused companies
  - Orderbot - an integrated cloud-based operations management platform centered around the complete order lifecycle
- The Company's highly scalable platform provides full brand control, depth of features and the operational flexibility needed to run dynamic retail operations and employ responsive web design
- Workarea bills its clients an annual license fee; Orderbot bills a one-time fee to clients for set up along with an annual license fee

## Thesis

- E-Commerce grew at a rate of 14% YoY in 2017, and this growth trend is expected to continue well past 2020
- Offline retail achieved a mere 3.1% YoY growth during the same period
- WebLinc is positioned to help B2B and B2C companies provide the omnichannel experience that customers now expect
- Workarea, the Company's main product, is the only digital commerce platform built on a modern tech stack uniting commerce, content and insights in one application

## Summary

Origin: August 2014

Capital: \$15.9M

Ownership: 39% Primary

Financing Rounds: Series A

Other Investors: Founders

Board Member: Steve Grenfell

## Revenue Model

WebLinc generates revenue as a tech-enabled service. The Company bills a one-time fee to its clients during the process of making their eCommerce sites live. Once the eCommerce site is launched, WebLinc generates revenue via both one-time hourly custom development services and monthly contractual services as well as annual license fees. Most clients pay for bulk hours per month or per year.

## Competitors

OneView Group plc, Shopify Inc., Zendesk, Inc., Corporation, PFSweb, Inc., SPS Commerce, Inc., Broadleaf Co., Ltd., Crexendo, Inc., Callidus Software Inc., Marketo, Inc.



## Company Overview

Market Segment:	Telemedicine
Headquarters:	Minneapolis, MN
CEO:	Jon Pearce
<ul style="list-style-type: none"> <li>- Zipnosis partners with health systems nationwide to provide a white-labeled virtual care platform, offering patients convenient access to care while improving clinician efficiency</li> <li>- Zipnosis guides health systems through the virtual care journey and guarantees launch of their virtual care platform in 60 days</li> <li>- Patients are treated through video, telephone and adaptive online interviews—with available pharmacy and lab integration</li> <li>- Provides real-time analytics and population health tools that help health systems optimize their workflows and better monitor their patients</li> </ul>	

## Thesis

- Ambulatory care telehealth market estimated at \$17B
- Focus on health systems and urgent care setting differentiates Zipnosis versus competitors; ability to leverage pre-existing groups of health providers (employed by the health system or through a third party) allows for SaaS margins in services-driven space
- Revenue model based on monthly recurring revenue fees paid by a health system, not on per visit fees, providing revenue visibility / stability
- Expansion into chronic and subspecialty care leveraging same technology and business model
- Zipnosis+ provides a framework for additional solutions to be added according to health system needs

## Summary

Origin:	December 2015
Capital:	\$10.0M
Ownership:	38% Primary
Financing Rounds:	Series A, Series B
Other Investors:	Arthur Ventures, Ascension Ventures, Affinity Ventures, Fairview Health Services, Hyde Park Venture Partners, Waterline Ventures
Board Member:	Gary Kurtzman

## Revenue Model

Zipnosis' revenue model is based on monthly recurring revenue fees paid by a health system, not on per visit fees.

## Competitors

MDLive, Doctor on Demand, Teladoc, American Well, Bright MD, Avizia, Intellivisit



- Founded in 1953 and NYSE-listed since 1971
- Safeguard provides capital and experience to growing healthcare, digital media and technology businesses
- Provides financial and management support for existing partner companies
- Distinguished track record of fostering innovative disruptive market leaders
- Attractive portfolio of tech-enabled companies across several verticals
- Safeguard adopted a change in business strategy and operations in early 2018
- Have realized over \$180 million in cash proceeds since change in strategy
- Using partner company monetization events to return value to shareholders



# Corporate Presentation

August 2019

SFE  
**LISTED**  
NYSE